Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4306501 | 0.79 | ALDH1A1 (0.51) | RAB9ANPC1MAPTCA1CA9 | |
| SCHEMBL103158 | 0.76 | MAOB (0.63) | MAOBMAOAGRM4ALOX5RAB9A | |
| SCHEMBL30036439 | 0.76 | MAOB (0.63) | MAOBMAOAGRM4ALOX5RAB9A | |
| SCHEMBL2150499 | 0.72 | MAOB (0.59) | MAOBMAOAGRM4ALOX5RAB9A | |
| SCHEMBL5583016 | 0.70 | NPC1 (0.45) | MAOBMAOAGRM4ALOX5RAB9A | |
| SCHEMBL2149640 | 0.70 | MAOB (0.57) | MAOBMAOAGRM4ALOX5RAB9A | |
| SCHEMBL7125605 | 0.70 | MAOB (0.68) | MAOBMAOAGRM4ALOX5RAB9A | |
| SCHEMBL19433431 | 0.69 | NPC1 (0.51) | MAOBMAOAGRM4ALOX5RAB9A | |
| SCHEMBL731363 | 0.69 | MAOB (0.71) | MAOBMAOAALOX5RAB9ANPC1 | |
| SCHEMBL12854020 | 0.69 | MAOB (0.71) | MAOBMAOAGRM4ALOX5RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779168-B2 | Lactone compounds and materials made therefrom | TRANSITIONS OPTICAL, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-7879881-B2 | 1-[[3-[(1,4,5,6-Tetrahydro-2-pyrimidinyl)amino]phenyl]acetyl]-4-piperidinepropanoic acid; new class of selective modulator of beta 3, beta 5 or dual integrin receptors; anticarcinogenic, antiinflammatory, antidiabetic agent | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-01 | — | — | US | claimed |
| EP-1539739-B1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-24 | — | — | EP | claimed |
| JP-4554364-B2 | — | — | 2010-09-29 | — | — | JP | claimed |
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-03-06 | — | — | US | claimed |
| EP-1539739-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-15 | — | — | EP | claimed |
| US-20040077684-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, NV (BE) | 2004-04-22 | — | — | US | claimed |
| WO-2004020435-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-11 | — | — | WO | claimed |
| EP-3659609-B1 | THERAPEUTIC AGENT FOR FIBROSIS | KYORIN SEIYAKU KK (JP) | 2024-05-08 | — | — | EP | disclosed |
| US-20240016937-A1 | COMPOSITION CONTAINING NUCLEIC ACID MOLECULE STABLY | TORAY INDUSTRIES, INC. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-11326163-B2 | Therapeutic agent for fibrosis | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2022-05-10 | — | — | US | disclosed |
| US-20210087556-A1 | THERAPEUTIC AGENT FOR FIBROSIS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3659609-A1 | THERAPEUTIC AGENT FOR FIBROSIS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2020-06-03 | — | — | EP | disclosed |
| EP-3098230-B1 | THIOETHER COMPOUND FOR THE PROTECTION OF THE 2'-HYDROXY GROUP IN NUCLEOSIDES TO BE USED IN OLIGONUCLEOTIDE SYNTHESIS. | BONAC CORP (JP) | 2020-05-06 | — | — | EP | disclosed |
| EP-1718635-A1 | PIPERIDINYL TARGETING COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082889-A1 | PIPERIDINYL TARGETING COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-09 | — | — | WO | disclosed |
| EP-1539739-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-15 | — | — | EP | disclosed |
| US-20040224986-A1 | Piperidinyl targeting compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, NV (BE) | 2004-11-11 | — | — | US | disclosed |
| US-20040077684-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, NV (BE) | 2004-04-22 | — | — | US | disclosed |
| WO-2004020435-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | ITGB3, ITGAV, ITGA2B | MAOB 4570/4885MAOA 4735/4885GRM4 1592/4885 |
| US-20210087556-A1 | THERAPEUTIC AGENT FOR FIBROSIS | SMAD3, SMAD2, NEK6 | MAOB 3963/4885MAOA 3640/4885GRM4 4142/4885 |
| US-20040077684-A1 | Piperidinyl compounds that selectively bind integrins | ITGB3, ITGAV, ITGA2B | MAOB 4570/4885MAOA 4735/4885GRM4 1592/4885 |
| US-11326163-B2 | Therapeutic agent for fibrosis | SMAD3, SMAD2, NEK6 | MAOB 3963/4885MAOA 3640/4885GRM4 4142/4885 |
| US-20240016937-A1 | COMPOSITION CONTAINING NUCLEIC ACID MOLECULE STABLY | NSUN2, POLRMT, POLN | MAOB 4415/4885MAOA 4628/4885GRM4 4707/4885 |
| US-20040224986-A1 | Piperidinyl targeting compounds that selectively bind integrins | ITGA5, ITGB5, ITGB1 | MAOB 4308/4885MAOA 4586/4885GRM4 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.